Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report.

dc.contributor.authorNowrouzi, Ali
dc.contributor.authorKafiabasabadi, Sepideh
dc.contributor.authorRodriguez-Calzadilla, Mario
dc.contributor.authorBenitez-Del-Castillo, Javier
dc.contributor.authorSoto-Guerrero, Alejandro
dc.contributor.authorDiaz-Ramos, Antonio
dc.contributor.authorMarques-Cavalcante, Kyara Vaneska
dc.date.accessioned2025-01-07T12:55:38Z
dc.date.available2025-01-07T12:55:38Z
dc.date.issued2021-05-29
dc.description.abstractWe report our findings in a patient who developed central retinal vein occlusion (CRVO) and was a chronic user of olanzapine, an antipsychotic medication. A 50-year-old Caucasian man, non-smoker, was referred to our clinic with the chief complaint of floater appearance in his left eye for the past 3 days. His past medical history indicated that he had been taking antipsychotic drugs (olanzapine) for about 3 years, with no other systemic disease or risk factors for CRVO. In the examination, his best-corrected visual acuity (BCVA) was 0.7 in the left eye. The fundus showed signs of nonischemic CRVO with subhyaloid hemorrhage and intraretinal hemorrhage in the posterior pole and superior and inferior retina, without macular edema, confirmed by optical coherence tomography (OCT). We ruled out other probable differential diagnoses and risk factors which lead to CRVO through a complete physical exam and blood analysis (complete blood count, glucose, urea, creatinine, lipid profile, erythrocyte sedimentation rate, C-reactive protein, prothrombin time, partial thromboplastin time, Bleeding time (BT), fibrinogen level, proteins, antiphospholipid antibodies, homocysteine blood level, antithrombin III, protein C and S, factor V Leiden, prothrombin mutation, angiotensin-converting enzyme level, other autoantibodies, and human leukocyte antigen [HLA]-B51). Finally, we confirmed the probable side effect of olanzapine in CRVO, which has not been previously reported. A possible pro-thrombogenic mechanism of olanzapine at the molecular level is an affinity for 5-HT2Aserotonin receptors. Blocking these receptors results in increased platelet aggregation and increased blood coagulability. These results indicate that CRVO can be a complication of chronic use of antipsychotic medications such as olanzapine, as shown for the first time in our case report. Clinicians should question patients who develop a sudden CRVO whether they are using antipsychotic medications such as olanzapine.
dc.identifier.doi10.1186/s13256-021-02865-8
dc.identifier.essn1752-1947
dc.identifier.pmcPMC8164284
dc.identifier.pmid34049568
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8164284/pdf
dc.identifier.unpaywallURLhttps://jmedicalcasereports.biomedcentral.com/track/pdf/10.1186/s13256-021-02865-8
dc.identifier.urihttps://hdl.handle.net/10668/25054
dc.issue.number1
dc.journal.titleJournal of medical case reports
dc.journal.titleabbreviationJ Med Case Rep
dc.language.isoen
dc.organizationSAS - Hospital Universitario de Jerez de la Frontera
dc.page.number307
dc.pubmedtypeCase Reports
dc.pubmedtypeJournal Article
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAntipsychotic drug
dc.subjectCentral retinal vein occlusion
dc.subjectMacular edema
dc.subjectOlanzapine
dc.subjectVenous thromboembolism
dc.subject.meshAntipsychotic Agents
dc.subject.meshHumans
dc.subject.meshMacular Edema
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOlanzapine
dc.subject.meshRetinal Vein Occlusion
dc.subject.meshVisual Acuity
dc.titleCentral retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number15

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC8164284.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format